Cargando…

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody

Detalles Bibliográficos
Autores principales:	Boyerinas, Benjamin, Jochems, Caroline, Hance, Kenneth W, Heery, Christopher R, Gulley, James L, Sabzevari, Helen, Schlom, Jeffrey, Tsang, Kwong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288783/ http://dx.doi.org/10.1186/2051-1426-2-S3-P96

Ejemplares similares

Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model
por: Lyon, Amanda, et al.
Publicado: (2014)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
por: Fujii, Rika, et al.
Publicado: (2016)

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
por: Jochems, Caroline, et al.
Publicado: (2013)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)
por: Boyerinas, Benjamin, et al.
Publicado: (2013)

Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
por: Tucker, Jo A., et al.
Publicado: (2012)

Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells
por: Madan, Ravi A, et al.
Publicado: (2013)

Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine
por: Farsaci, Benedetto, et al.
Publicado: (2013)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody‐dependent cellular cytotoxicity
por: Branstetter, Elaine, et al.
Publicado: (2021)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
por: Bilusic, Marijo, et al.
Publicado: (2019)

The role of soluble CD40L in immunosuppression
por: Schlom, Jeffrey, et al.
Publicado: (2013)

Identification of a HIV Gp41-Specific Human Monoclonal Antibody With Potent Antibody-Dependent Cellular Cytotoxicity
por: Yang, Zheng, et al.
Publicado: (2018)

The use of monoclonal antibody B72.3 in the management of gynecologic malignancies.
por: Simpson, J., et al.
Publicado: (1988)

An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells
por: Fantini, Massimo, et al.
Publicado: (2019)

Cellular cytotoxicity mediated by isotype-switch variants of a monoclonal antibody to human neuroblastoma.
por: d'Uscio, C. H., et al.
Publicado: (1991)

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
por: Jochems, Caroline, et al.
Publicado: (2017)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Product review: avelumab, an anti-PD-L1 antibody
por: Collins, Julie M., et al.
Publicado: (2018)

Molecular and cellular basis for immunomodulation with monoclonal antibodies
por: Melero, Ignacio
Publicado: (2015)

Influenza and Antibody-Dependent Cellular Cytotoxicity
por: Von Holle, Tarra A., et al.
Publicado: (2019)

Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity
por: Kwok, Hang Fai, et al.
Publicado: (2011)

Antibody–receptor interactions mediate antibody-dependent cellular cytotoxicity
por: Sun, Yue, et al.
Publicado: (2021)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
por: Lee, Maxwell Y., et al.
Publicado: (2021)

Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas
por: Tsang, Kwong yok, et al.
Publicado: (2022)

Human monoclonal antibodies and monoclonal antibody multispecificity.
por: Campbell, A. M., et al.
Publicado: (1987)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

Antibody-dependent-cellular-cytotoxicity against cultured human breast cancer cells mediated by human effector cells using monoclonal and polyclonal antibodies.
por: Gore, M. E., et al.
Publicado: (1983)

Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function
por: Gao, Rongyuan, et al.
Publicado: (2020)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
por: Faiena, Izak, et al.
Publicado: (2018)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
por: Rajan, Arun, et al.
Publicado: (2019)

Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
por: Vandeveer, Amanda, et al.
Publicado: (2015)

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
por: Jochems, Caroline, et al.
Publicado: (2016)

Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway
por: Mielke, Dieter, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q4o62of3d9qq18enh0kna9s1uf